retatrutide phase 2 trial results obesity Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide Before and After: Doctor

Gonzalez-Rellan MJ et al

Lee et al., 2020)

Some plans require a BMI of 30 or higher, while others may cover treatment at a BMI of 27 or higher when certain weight-related conditions are present

That's off label

Although leg cramps are not listed as an official adverse effect in FDA prescribing information, understanding the potential indirect mechanismsincluding dehydration, electrolyte imbalances, and nutritional changescan help patients and clinicians address this symptom effectively while continuing therapy

Hormone Therapy Can HelpBut Its Only Part of the Equation Hormone therapy (HT) can attenuate visceral fat gain by up to 60% , improve insulin sensitivity, and support muscle mass